Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats

European Journal of Pharmacology

Volumn 709, Issue 1-3, 2013, Pages 1-12

  Kumar, Anil ^a   Sharma, Neha ^a   Mishra, Jitendriya ^a   Kalonia, Harikesh ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Atorvastatin; IL 6; Malonic acid; Rofecoxib; Simvastatin; TNF

Indexed keywords

ACETYLCHOLINESTERASE; ATORVASTATIN; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; MALONALDEHYDE; NITRATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROFECOXIB; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; UBIQUINOL CYTOCHROME C REDUCTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; HUNTINGTON CHOREA; LOCOMOTION; LOW DRUG DOSE; MALE; MAZE TEST; MEMORY CONSOLIDATION; MENTAL FUNCTION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; ROTAROD TEST; TASK PERFORMANCE; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; COGNITION DISORDERS; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HEPTANOIC ACIDS; HUNTINGTON DISEASE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LACTONES; MALE; MALONATES; NEURONS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; OXIDATIVE STRESS; PYRROLES; RATS; RATS, WISTAR; SIMVASTATIN; SULFONES;

EID: 84877010337     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.03.042     Document Type: Article

References (69)

1. G. Bates Huntingtin aggregation and toxicity in Huntington's disease Lancet 361 2003 1642 1644
2. S.B. Berman, and T.G. Hastings Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease J. Neurochem. 73 1999 1127 1137
3. J. Botting Defining the role of COX-2 inhibitors in inflammatory and other diseases Drugs News Perspect. 13 2000 560 566
4. J.D. Boyd, H. Jang, K.R. Shepherd, C. Faherty, S. Slack, Y. Jiao, and R.J. Smeyne Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta Brain Res. 1175 2007 107 116
5. C.D. Breder, D. Dewitt, and R.P. Kraig Characterization of inducible cyclooxygenase in rat brain J. Comp. Neurol. 355 1995 296 315
6. L. Broom, L. Marinova-Mutafchieva, M. Sadeghian, J.B. Davis, A.D. Medhurst, and D.T. Dexter Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease Free Radic. Biol. Med. 50 2011 633 640
7. P. Calabresi, P. Gubellini, B. Picconi, D. Centzone, A. Pisani, P. Bonsi, P. Greengard, R.A. Hipskind, E. Borrelli, and G. Bernardi Inhibition of mitochondrial complex ΙΙ induces a long-term potentiation of NMDA mediated synaptic excitation in the striatum requiring endogenous dopamine J. Neurosci. 21 2001 5110 5120
8. N.V. Chandrasekharan, H. Dai, K.L. Roos, N.K. Evanson, J. Tomsik, T.S. Elton, and D.L. Simmons COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic drugs: cloning, structure and expression Proct. Natl. Acad. Sci. USA 99 2002 3926 3931
9. H. Chen, E. Jacobs, M.A. Schwarzschild, M.L. McCullough, E.E. Calle, M.J. Thun, and A. Ascherio Nonsteroidal anti-inflammatory drug use and the risk for Parkinson's disease Ann. Neurol. 58 2005 963 967
10. L. Chen, W.H. Haught, B. Yang, T.G. Saldeen, S. Parathasarathy, and J.L. Mehta Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of anti-atherosclerotic effects of vitamin E, lovastatin and amlodipine J. Am. Coll. Cardiol. 30 1997 569 575
11. F. Cicchetti, L. Prensa, Y. Wu, and A. Parent Chemical anatomy of basal interneurons in normal individuals and in patients with Huntington's disease Brain Res. Rev. 34 2000 80 101
12. A. Dedeoglu, R.J. Ferrante, O.A. Andreassen, W.H. Dilmann, and M.F. Beal Mice over expressing 70-kDa heat shock protein show increased resistance to malonate and 3-nitropropionic acid Exp. Neurol. 176 2002 262 265
13. R. Distl, S. Treiber-Held, F. Albert, V. Meske, K. Harzer, and T.G. Ohm Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain J. Pathol. 200 2003 104 111
14. D. del Toro, X. Xifro, A. Pol, S. Humbert, F. Saudou, J.M. Canals, and J. Alberch Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease J. Neurochem. 115 2010 153 167
15. G.L. Ellman Tissue sulfhydryl groups Arch. Biochem. Biophys. 82 1959 70 77
16. G.L. Ellman, D.K. Courtney, V. Andres, and R.M. Featherstone A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 7 1961 88 95
17. A.M. Estrada Sanchez, J. Mejía-Toiber, and L. Massieu Excitotoxic neuronal death and the pathogenesis of Huntington's disease Arch. Med. Res. 39 2008 265 276
18. B. Ferger, O. Eberhardt, P. Teismann, C. de Groote, and J.B. Schulz Malonate-induced generation of reactive oxygen species in rat striatum depends on dopamine release but not on NMDA receptor activation J. Neurochem. 73 1999 1329 1332
19. C. Franke, M. Noldner, R. bdel-Kader, L.N. Johnson-Anuna, W. Gibson Wood, W.E. Muller, and G.P. Eckert Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment Neurobiol. Dis. 25 2007 438 445
20. V. Gaur, and A. Kumar Effect of nonselective and selective COX-2 inhibitors on memory dysfunction, glutathione system, and tumor necrosis factor alpha level against cerebral ischemia reperfusion injury Drug Chem. Toxicol. 35 2012 218 224
21. V. Gaur, and A. Kumar Neuroprotective potentials of candesartan, atorvastatin and their combination against stroke induced motor dysfunction Inflammopharmacology 19 2011 205 214
22. E. Ginter, and V. Simko Statins: the drugs for the 21st century Bratisl. Lek. Listy. 110 2009 664 668
23. L.C. Green, D.A. Wagner, J. Glgowski, P.L. Skipper, J.S. Wishnok, and S.R. Tannenbaum Analysis of nitrate, nitrite, and 15[N] nitrate in biological fluids Ann. Biochem. 44 1982 332 336
24. A. Gupta, A. Dhir, A. Kumar, and S.K. Kulkarni Protective effect of cyclooxygenase (COX)-inhibitors against drug induced catatonia and MPTP-induced striatal lesion in rats Pharmacol. Biochem. Behav. 94 2009 219 226
25. G.J. Harry, and A.D. Kraft Neuroinflammation and microglia: considerations and approaches for neurotoxicity assessment Expert Opin. Drug Metab. Toxicol. 4 2008 1265 1277
26. T.G. Hastings Enzymatic oxidation of dopamine: The role of prostaglandin H synthase J. Neurochem. 64 1995 919 924
27. E.C. Hirsch, and S. Hunot Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8 2009 382 397
28. D.R. Huntjens, D.J. Spalding, M. Danhof, and O.E. Della Pasqua Differences in the sensitivity of behavioral measures of pain to the selectivity of cyclo-oxygenase inhibitors Eur. J. Pain 13 2009 448 457
29. H. Kalonia, J. Mishra, and A. Kumar Targeting neuro-inflammatory cytokines and oxidative stress by minocycline attenuates quinolinic-acid-induced Huntington's disease-like symptoms in rats Neurotox. Res. 22 2012 310 320
30. H. Kalonia, P. Kumar, and A. Kumar Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats Behav. Brain Res. 216 2011 220 228
31. H. Kalonia, P. Kumar, and A. Kumar Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats Brain Res. 1372 2011 115 126
32. H. Kalonia, P. Kumar, A. Kumar, and B. Nehru Protective effect of rofecoxib and nimesulide against intra-striatal quinolinic acid-induced behavioral, oxidative stress and mitochondrial dysfunctions in rats Neurotoxicology 31 2010 195 203
33. H. Kalonia, P. Kumar, and A. Kumar Targetting oxidative stress attenuates malonoic acid induced Huntington like behavioural and mitochondrial alterations in rats Eur. J. Pharmacol. 634 2010 46 52
34. H. Kalonia, P. Kumar, A. Kumar, and B. Nehru Effect of caffeic acid and rofecoxib and their combination against intrastriatal quinolinic acid induced oxidative damage, mitochondrial and histological alterations in rats Inflammopharmacology 17 2009 211 219
35. A. Kent Huntington's disease Nurs. Stand. 18 2004 45 51
36. T.E. King Preparation of succinate dehydrogenase and reconstitution of succinate oxidase Methods Enzymol. 10 1967 322 331
37. T.E. King, and R.L. Howard Preparations and properties of soluble NADH dehydrogenases from cardiac muscle Methods Enzymol. 10 1967 275 284
38. P. Klivenyi, O.A. Andreassen, R.J. Ferrante, A. Dedeoglu, G. Mueller, E. Lancelot, M. Bogdanov, J.K. Andersen, D. Jiang, and M.F. Beal Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine J. Neurosci. 20 2000 1 7
39. W.J. Koroshetz, B.G. Jenkins, B.R. Rosen, and M.F. Beal Energy metabolism defects in Huntington's disease and effects of coenzyme Q10 Ann. Neurol. 41 1997 160 165
40. A. Kumar, A. Prakash, D. Pahwa, and J. Mishra Montelukast potentiates the protective effect of rofecoxib against kainic acid-induced cognitive dysfunction in rats Pharmacol. Biochem. Behav. 103 2012 43 52
41. A. Kumar, N. Seghal, S.V. Padi, and P.S. Naidu Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats Eur. J. Pharmacol. 551 2006 58 66
42. A. Kumar, N. Sharma, A. Gupta, H. Kalonia, and J. Mishra Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms Brain Res. 1471 2012 13 22
43. P. Kumar, S.S. Padi, P.S. Naidu, and A. Kumar Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms Fundam. Clin. Pharmacol. 21 2007 297 306
44. C.S. Lobsinger, and D.W. Cleveland Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease Nat. Neurosci. 10 2007 1355 1360
45. O.H. Lowry, N.J. Rosenbrough, A.l. Farr, and R.J. Randal Protein measurement with Folin-Phenol reagent J. Biol. Chem. 193 1951 265 275
46. H. Luck Catalase H.U. Bergmeyer, Methods of Enzyme Analysis 1971 Academic Press New York 885 893
47. R.T. Matthews, L. Yang, B.G. Jenkins, R.J. Ferrante, B.R. Rosen, R. Kaddurah-Daouk, and M.F. Beal Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease J. Neurosci. 18 1998 156 163
48. R. Morris Development of a water-maze procedure for studying spatial learning in the rat J. Neurosci. Methods 11 1984 47 60
49. T. Mosmann Rapid colorimetric assay for cellular growth survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63
50. L.Y. Moy, G.D. Zeevalk, and P.K. Sonsalla Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures J. Neurochem. 74 2000 1656 1665
51. S. Patassini, C. Giampa, A. Martorana, G. Bernardi, and F.R. Fusco Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease Neurosci. Lett. 448 2008 166 169
52. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 6th edition 2007 Academic Press San Diego
53. V. Perez-De La Cruz, D. Elinos-Calderon, Y. Robledo-Arratia, O.N. Medina-Campos, J. Pedraza-Chaverri, S.F. Ali, and A. Santamaria Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease Behav. Brain Res. 199 2009 210 217
54. A.C. Ross Huntington's disease: a clinical review Orphanet J. Rare Dis. 5 2010 40 47
55. J.I. Rossato, G. Zeni, C.F. Mello, M.A. Rubin, and J.B. Rocha Ebselen blocks the quinolinic acid-induced production of thiobarbituric acid reactive species but does not prevent the behavioral alterations produced by intra-striatal quinolinic acid administration in the rat Neurosci. Lett. 318 2002 137 140
56. M. Saldana, L. Pujols, J. Roca-Ferrer, A. Cardozo, E. Aguilar, M. Bonastre, and C. Marin Relevance of COX-2 gene expression in dementia with lewy bodies associated with Alzheimer pathology Movement Disord. 23 2008 804 810
57. J.B. Schulz, P.L. Huang, R.T. Matthews, D. Passov, M.C. Fishman, and M.F. Beal Striatal malonate lesions are attenuated in neuronal nitric oxide synthase knockout mice J. Neurochem. 67 1996 430 433
58. K. Simons, and R. Ehehalt Cholesterol, lipid rafts, and disease J. Clin. Invest. 110 2002 597 603
59. G.L. Sottocasa, B. Kuylenstierna, L. Ernster, and A. Bergstrand An electron transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study J. Cell Biol. 32 1967 415 438
60. I. Tasset, F. Sanchez, and I. Tunez The molecular bases of Huntington's disease: a role played by oxidative stress Rev. Neurol. 49 2009 424 429
61. M. Valenza, and E. Cattaneo Cholesterol dysfunction in neurodegenerative diseases: is Huntington's disease in the list? Prog. Neurobiol. 80 2006 165 176
62. M. Vila, and S. Przedborski Targeting programmed cell death in neurodegenerative diseases Nat. Rev. Neurosci. 4 2003 365 375
63. M. Vila, D. Ramonet, and C. Perier Mitochondrial alterations in Parkinson's disease: new clues J. Neurochem. 107 2008 317 328
64. A.H. Wagner, T. Kohler, U. Ruckschloss, I. Just, and M. Hecker Improvement of nitric oxide-dependent vasodilation by HMG-CoA reducatse inhibitors through attenuation of endothelial superoxide anion formation Arterioscler. Thromb. Vasc. Biol. 20 2000 61 69
65. F.O. Walker, and L.A. Raymond Targeting energy metabolism in Huntington's disease Lancet 364 2004 312 313
66. X.M. Wang, X. Gao, X.H. Zhang, Y.Y. Tu, M.L. Jin, G.P. Zhao, L. Yu, N.H. Jing, and B.M. Li The negative cell cycle regulator, Tob (transducer of ErbB-2), is involved in motor skill learning Biochem. Biophy. Res. Commun. 340 2006 1023 1027
67. S. Wassmann, U. Laufs, A.T. Baumer, K. Muller, C. Konkol, H. Sauer, M. Bohm, and G. Nickenig Inhibition of geranylation reduces angiotensin ΙΙ-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac 1 GTPase Mol. Pharmacol. 59 2001 646 654
68. E.D. Wills Mechanisms of lipid peroxide formation in animal tissues Biochem. J. 99 1966 667 676
69. G.D. Zeevalk, L. Manzino, and P.K. Sonsalla NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum Exp. Neurol. 161 2000 638 646